http://www.onclive.com/onclive-tv/dr-sabbatini-on-novel-approaches-with-ip-therapy-for-ovarian-cancer
Dr. Sabbatini on Novel Approaches With IP Therapy For Ovarian Cancer

Paul Sabbatini, MD



Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses novel approaches for IP therapy for patients with ovarian cancer.

Dose-dense therapy or every-3-week therapy allows for many additional combinations in the primary setting, explains Sabbatini. Adding PARP inhibitors, maintenance therapy, anti-vascular agents, or other novel compounds are currently being investigated.

According to Sabbatini, it would be difficult to incorporate those into an IP with cisplatin.
 
Printer Printing...